FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising

The FDA granted accelerated approval to Bayer’s Hyrnuo (sevabertinib) for adults with locally advanced or metastatic non‑squamous NSCLC bearing HER2 TKD activating mutations after prior systemic therapy and approved the Oncomine Dx Target Test as a companion diagnostic; Hyrnuo’s monthly list price is reported at $24,000 and the recommended dose is 20 mg orally twice daily. In clinical cohorts, 70 patients who were prior-systemic-therapy treated but naive to HER2-targeted therapy had a confirmed ORR of 71% (median DOR 9.2 months; 54% ≥6 months), while a separate 52‑patient group showed an ORR of 38% (median DOR 7.0 months; 60% ≥6 months). Separately, the FDA granted full approval to Amgen’s Imdelltra (tarlatamab‑dlle) for ES‑SCLC after platinum chemotherapy, with the Phase 3 DeLLphi‑304 trial showing a 40% reduction in risk of death and a >5‑month median overall survival benefit versus standard chemotherapy.

Analysis

The FDA granted accelerated approval to Bayer AG's Hyrnuo (sevabertinib) for adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 TKD activating mutations after prior systemic therapy and approved the Oncomine Dx Target Test as a companion diagnostic. In a study cohort of 70 prior-systemic-therapy patients naive to HER2-targeted therapy, confirmed objective response rate (ORR) was 71% with median duration of response (DOR) 9.2 months and 54% of responders had DOR ≥ 6 months; a separate 52-patient cohort showed ORR 38% with median DOR 7.0 months and 60% of responders ≥ 6 months. The recommended sevabertinib dose is 20 mg orally twice daily with food and Reuters reports a monthly list price of $24,000, indicating material per-patient revenue potential if uptake and reimbursement follow approval. Separately, the FDA granted full approval to Amgen’s Imdelltra for ES-SCLC after platinum chemotherapy based on the Phase 3 DeLLphi-304 result showing a 40% reduction in risk of death and >5-month median overall survival benefit versus standard-of-care; market signals are moderately positive (sentiment_score 0.6) with strong per-ticker sentiment for AMGN (0.8), suggesting favorable investor reception but dependence on real-world uptake and payer coverage.

Key Decisions for Investors

• Monitor Bayer (BAYRY) commercial launch metrics and Oncomine Dx adoption closely, since the $24,000 monthly list price and the 71% ORR cohort suggest meaningful revenue per treated patient if reimbursement and testing scale
• Favorably reassess exposure to Amgen (AMGN) given Imdelltra's full approval and the 40% mortality risk reduction in Phase 3, but validate thesis against early sales, clinician uptake, and any safety or label-clarifying data
• Implement risk controls around Hyrnuo: watch for real-world durability (DOR) and payer coverage decisions as primary catalysts, and consider limiting position size until initial commercial and post-approval data confirm trial outcomes